Abstract Two series of novel 4-chloro-2-(benzylthio)-5-(1,3,4-oxadiazol-2-yl)benzenesulfonamides and their N-aroyl derivatives have been synthesized and evaluated for in vitro anticancer activity against the full NCI-60 cell line panel. Most of the compounds exhibited antiproliferative activity. Among them a compound bearing an N-(thien-2-ylcarbonyl) moiety showed broad-spectrum activity with 50% growth inhibition (GI 50 ) values in the range of 2.02-7.82 lM over 50 cell lines.
Introduction
Aryl-and heteroarylsulfonamides are an important class of therapeutic agents in current medicinal science [1] . Various arylsulfonamides have been reported to possess anticancer [2] [3] [4] [5] [6] and/or anti-human immunodeficiency virus (HIV) properties [6, 7] . Our systematic studies on the synthesis of 1,4,2-benzodithiazine 1,1-dioxides and their subsequent transformations into 2-mercaptobenzenesulfonamide (MBSA) derivatives ( Fig. 1 ) having a variety of heterocyclic ring systems or acyclic polynitrogen moieties at the sulfonamide functionality resulted in promising anticancer [8] [9] [10] [11] [12] [13] , HIV antiviral [14] [15] [16] , or antibacterial agents [17] as well as potent inhibitors of transmembrane cancer-associated carbonic anhydrase isozymes hCAIX and hCAXII [18, 19] .
A number of structurally novel N-acylbenzenesulfonamides have recently been reported either as potent antitumor agents against a broad spectrum of human tumor xenografts (colon, lung, breast, ovary, and prostate) in nude mice [22] (Fig. 2) or clinically investigated drug candidates with cytostatic activity against malignant tumors such as Eli Lilly's tasisulam sodium [23] or Abbott's WO-2002024636, ABT-737 [24] , and ABT-263 [25] (Fig. 3) .
This led us to an assumption that expansion of the series of 2-mercapto-N-acylbenzenesulfonamide potential anticancer agents, in which groups of varying size and electronic properties are placed at positions 2, 5, and N-of the benzenesulfonamide ring, may shed light on the structural features contributing to the biological activities.
Results and discussion

Chemistry
Several methods for synthesis of 2-mercaptobenzenesulfonamides are known. The simplest and most efficient method employs the ring-opening reaction of preformed 3-mercapto-1,1-dioxo-1,4,2-benzodithiazine derivatives under alkaline conditions [27] . Alternatively, access to 2-mercaptobenzenesulfonamides is provided by direct reaction of 2-halogenobenzenesulfonamides with sodium polysulfide (Na 2 S x ) [28] or conversion of 2-aminobenzenesulfonamides via diazonium salt decomposition utilizing disodium sulfide (Na 2 S) or potassium ethyl xanthate [28] [29] [30] . Herein, we report a direct synthetic route to novel 4-chloro-2-benzylthiobenzenesulfonamides and their N-acylated derivatives. Due to our ongoing research in the field of biologically active 2-mercaptobenzenesulfonamides with five-membered rings incorporated in 5-position of the MBSA scaffold [9] , we choose 1,3,4-oxadiazole as our model heterocyclic residue.
The expected 1,3,4-oxadiazoles 1a, 1b were conveniently prepared in good yields by the reaction of 2,4-dichloro-5-sulfamoylbenzhydrazide [31] with orthoesters in refluxing glacial acetic acid (Scheme 1).
We found that 2,4-dichloro-5-(1,3,4-oxadiazol-2-yl) benzenesulfonamide (1a) under standard conditions (BnSH/ K 2 CO 3 /DMF (N,N-dimethylformamide)/RT) undergoes a selective S N Ar addition-elimination reaction in 2-position. Moderate yields (14-58%, Table 1 , entries 1-4, 6, and 8) of this reaction led us to optimize the conditions. Higher yields were observed when tetrabutylammonium bromide (TBAB) was used as a phase-transfer catalyst, especially in acetonitrile/water (300:1, v/v) reaction environment ( Table 1 , entry 9). Slight decrease of substrate conversion was observed in the absence of argon atmosphere (Scheme 1).
The desired N-acylsulfonamides 4a-4j (Scheme 2) were prepared by carbodiimide-mediated coupling of aromatic carboxylic acids with sulfonamides [32] [33] [34] solvent. In some cases crystalline 4-(N,N-dimethylamino)pyridinium N-heteroaroylsulfonamidates (3a-3c) were isolated and characterized, which by treatment with 10% (w/v) ethanolic p-toluenesulfonic acid (p-TSA) solution were converted to the desired N-acylsulfonamides 4a-4c.
In vitro biological activity
Compounds 2a-2d and 4a-4j submitted to National Cancer Institute (NCI) were evaluated for their in vitro anticancer activity. Sulfonamides 2a and 2c showed significant selectivity toward leukemia cell line CCRF-CEM (Fig. 4) , whereas 2d appears to be substantially inactive. HOP-92, non-small cell lung cancer, and renal cancer A498 cell lines reveal some insight into structure-activity relationship (SAR). Cytostatic activity of 2a-2c toward those cell lines increases when CLogP and calculated molar refractivity (CMR) of the compound increase (Table 2) .
Over a series of N-(thien-2-ylcarbonyl)benzenesulfonamide derivatives (4c-4g), substitution on the heterocyclic (4e, 4f: R 1 = Me) or benzylthio (4d, 4f: R 2 = Cl) moiety decreases activity significantly. It seems interesting that closely related six-membered N-heteroaroyl derivatives (4a, 4b, and 4h) showed no activity, which renders 4c as a lead for further optimization.
Compound 4c (NSC 754633) which satisfied predetermined threshold inhibition criteria was selected for the NCI five-dose (0.01-100 lM) assay and exhibited remarkable anticancer activity against most of the tested cell lines representing nine different subpanels (Table 3) . Only NCI/ ADR-RES (adriamycin-resistant cell line) expressing high levels of MDR1 and Pgp-170 glycoprotein [36, 37] was found to be insensitive at the highest tested concentration (100 lM). The obtained data revealed some subpanel sensitivity toward renal, central nervous system (CNS), and breast cancer cell lines (subpanel selectivity ratio: 1.04-1.46). The CNS cancer subpanel showed highest sensitivity with mean GI 50 value of 3.24 lM and mean concentration causing total growth inhibition at 12.68 lM level. It is worth mentioning that the cytotoxic effect of 4c was less pronounced in the leukemia subpanel [50% lethal concentration (LC 50 ) for all tested leukemia cell lines [100 lM]. A relatively large difference in mean cytostatic (mean-graph GI 50 = 4.27 lM) and cytotoxic (mean-graph LC 50 = 58.88 lM) indicators could be projected to potential low toxicity against normal cells resulting in a broad therapeutic index. 
Scheme 2
Synthesis and in vitro activity 977 COMPARE [38, 39] analysis at the NCI of compound 4c showed moderate Pearson correlation coefficient (PCC = 0.446-0.549) with DNA interfering agents such as actinomycin D, echinomycin, bruceantin, chromomycin A3, or didemnin B (Table 4) .
Conclusions
We designed a new and efficient method of obtaining substituted 2-mercaptobenzenesulfonamides from readily available 2,4-dichlorobenzenesulfonamides under optimized mild phase-transfer catalysis conditions. This approach offers easy and quick isolation of the products and preparative-scale synthesis. Novel 2-mercaptobenzenesulfonamides and their structurally diverse N-(hetero)aroyl derivatives were evaluated for in vitro antiproliferative activity. The discovered N-acylbenzenesulfonamide 4c shows promising anticancer activity toward 50 human cancer cell lines and could be considered as a lead for further optimization.
Experimental
Melting points were determined with a Boëtius apparatus. Infrared (IR) spectra were taken using a Thermo Mattson Satellite FTIR spectrophotometer, 1 H and 13 C nuclear magnetic resonance (NMR) were taken with a Varian Gemini 200 MHz or Varian Unity Plus 500 MHz spectrometer. Chemical shifts are reported in ppm (d). The results of elemental analyses for C, H, and N were in agreement with the calculated values within ±0.4% range. Column chromatography was carried out on silica gel Fluka Silica gel 60 (0.035-0.070 mm). The starting 2,4-dichloro-5-sulfamoylbenzhydrazide was obtained from commercially available 2,4-dichloro-5-sulfamoylbenzoic acid according to methods described previously [31] .
General procedure for the synthesis of 1a, 1b A mixture of 2.84 g 2,4-dichloro-5-sulfamoylbenzhydrazide (10 mmol) and the appropriate orthoester (60 mmol) in 30 cm 3 glacial AcOH was refluxed for 7-12 h. After cooling to room temperature, stirring was continued overnight. The precipitate was filtered off, washed with cold EtOH and petroleum ether, and purified by crystallization from EtOH. 
General procedure for the synthesis of 2a-2d
To a suspension of the appropriate 2,4-dichlorobenzenesulfonamide 1a, 1b (5 mmol) in 30 cm 3 MeCN and 0.1 cm 3 water, 1.52 g K 2 CO 3 (11 mmol) and 0.016 g TBAB (0.05 mmol) were added. The obtained reaction mixture was vigorously stirred under an argon atmosphere, and slowly the appropriate mercaptan (5 mmol) was added dropwise. After 24 h of stirring at room temperature, the reaction mixture was concentrated under reduced pressure to dryness, and 15 cm 3 EtOH was added. The precipitate was filtered off and suspended in 30 cm 3 water, stirred for 30 min, and filtered off. The crude product was purified by crystallization from EtOH. 
2-Benzylthio
-4-chloro-5-(1,3,4-oxadiazol-2-yl)benzenesulfonamide (2a
General procedure for the synthesis of 2-benzylthio-4-chloro-5-(1,3,4-oxadiazol-2-yl)-4-(N,N-dimethylamino)pyridinium N-acylbenzenesulfonamidates 3a-3c
To the appropriate carboxylic acid (1.1 mmol) in 5 cm 3 dry MeCN, 0.212 g 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 1.1 mmol) was added and stirred for 5 min. 2a (0.382 g, 1 mmol) and 0.256 g DMAP (2.1 mmol) were added, and the reaction mixture was stirred at room temperature overnight. The precipitate was filtered off and washed with cold MeCN and MeOH. The crude salt was purified by crystallization from MeOH. 1,607, 1,588, 1,562, 1,496, 1,324 1,591, 1,565, 1,315, 1,138 
General procedure for the synthesis of N-acylbenzenesulfonamides 4a-4c
To a suspension of the appropriate pyridinium salt 3a-3c (0.5 mmol) in 5 cm 3 EtOH, 2 cm 3 10% p-TSA solution in EtOH was added and stirred at room temperature for 1 h. The precipitate was filtered off and washed with EtOH and water. 1,730, 1,647, 1,590, 1,530, 1,496, 1,450, 1 925, 2,854, 1,658, 1,591, 1,577, 1,525, 1,495, 1,453 683, 1,592, 1,559, 1,531, 1,472, 1,351, 1 
NCI in vitro anticancer screen
As of early 2007 all compounds submitted to the NCI-60 cell screen are tested initially at a single high dose (10 lM) in the full NCI-60 cell panel representing human leukemia, melanoma and lung, colon, brain, breast, ovary, kidney, and prostate cancers. Briefly, the compounds were solubilized in DMSO and added at a single concentration, and the cell culture was incubated for 48 h at 37°C, 5% CO 2 , 95% air, and 100% relative humidity. End points were determined by colorimetric sulforhodamine B (SRB) assay [40] . Results for each compound were reported as a mean-graph of the percent growth of the treated cells relative to the nodrug control, and relative to the time-zero number of cells. This allows detection of both growth inhibition (values between 0 and 100) and lethality (values less than 0) [41] . According to Developmental Therapeutics Program (DTP) anticancer screening paradigm, after obtaining the results for one-dose assay, careful analysis of DTP screening data was performed and compound 4c (NSC 754633) which satisfied predetermined threshold inhibition criteria was selected for the NCI five-dose (0.01-100 lM) assay. The results were used to create dose-response curves (log 10 of sample concentration versus % growth), and three response parameters (GI 50 , TGI, and LC 50 ) were calculated for each cell line. GI 50 measures the growth inhibitory power of the test agent, TGI signifies a cytostatic effect, and LC 50 signifies a cytotoxic effect.
